What question did this study set out to answer?

To compare the pharmacokinetic profiles of free adriamycin versus DNA-complexed adriamycin in pediatric patients with malignant disease.

March 1, 1978Acta Pharmacologica et Toxicologica

A Pharmacokinetic Evaluation of Free and DNA‐Complexed Adriamycin: A Preliminary Study in Children with Malignant Disease

View Full Paper

Ask AI

Bookmark

Why the study?

Does DNA-complexed adriamycin alter pharmacokinetics compared to free adriamycin in children with malignant disease?

Population

6 children with malignant disease

Comparison

DNA-complexed adriamycin vs Free adriamycin

Design

Other

Authors

MKMartin KummenOslo University Hospital KLKai K. LieNorwegian Institute of Marine Research SLSverre O. LieOslo University Hospital

Discussion

Member takes

Implication

May warrant caution with DNA-complexed adriamycin in children; leaves open therapeutic implications pending controlled trials.

Key Points

To compare the pharmacokinetic profiles of free adriamycin versus DNA-complexed adriamycin in pediatric patients with malignant disease.
Conducted a within-subject crossover evaluation in 6 children with malignant disease, administering free and DNA-complexed adriamycin 3 to 4 weeks apart.
Collected plasma and urine samples during and following drug infusion.
Quantified drug and fluorescent metabolite concentrations using a sensitive fluorimetric assay.
Administration of DNA-complexed adriamycin resulted in markedly higher plasma concentrations of the drug compared to the free form.
Urinary excretion of adriamycin and its fluorescent metabolites was lower following infusion of the DNA-complexed formulation than with the free drug.

Structured PICO

Does DNA-complexed adriamycin alter pharmacokinetics compared to free adriamycin in children with malignant disease?

Population

6 children with malignant disease

Intervention

DNA-complexed adriamycin

Comparator

Free adriamycin (administered to the same child at 3-4 week intervals)

Outcome

Pharmacokinetics (plasma concentration and urine excretion of adriamycin and fluorescent metabolites)surrogate

DNA-complexed adriamycin significantly alters the pharmacokinetic profile in children with malignancies, leading to higher plasma levels and reduced urinary excretion.

Cite This Study

Kummen et al. (1978) studied this question.

synapsesocial.com/papers/6a70d67f75498292b70a5083 https://doi.org/10.1111/j.1600-0773.1978.tb02192.x

View Full Paper

Ask AI

Bookmark

A Pharmacokinetic Evaluation of Free and DNA‐Complexed Adriamycin: A Preliminary Study in Children with Malignant Disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A Pharmacokinetic Evaluation of Free and DNA‐Complexed Adriamycin: A Preliminary Study in Children with Malignant Disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider